{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:29Z","timestamp":1792839689389,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40121-025-01145-y","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:18:03Z","timestamp":1744240683000},"page":"1089-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03042520","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chung-Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Tsung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Soo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horng-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.-Shyan","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Youn-Jae\u00a0Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1145_CR1","unstructured":"Interim guidance for country validation of viral hepatitis elimination. https:\/\/www.whoint\/publications\/i\/item\/9789240028395. Accessed 08 Oct 2024."},{"issue":"5","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"Polaris Observatory HCV Collaborators","year":"2022","unstructured":"Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396\u2013415.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","volume":"20","author":"CF Huang","year":"2022","unstructured":"Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162.e1156.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.14309\/ajg.0000000000000606","volume":"115","author":"CF Huang","year":"2020","unstructured":"Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, et al. Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol. 2020;115(8):1226\u201335.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12072-018-9908-4","volume":"12","author":"CF Huang","year":"2018","unstructured":"Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Lin ZY, et al. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hep Intl. 2018;12(6):544\u201351.","journal-title":"Hep Intl"},{"issue":"6","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s12072-020-10105-2","volume":"14","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hep Intl. 2020;14(6):1023\u201333.","journal-title":"Hep Intl"},{"issue":"7","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/1078-0432.CCR-16-0921","volume":"23","author":"ML Yu","year":"2017","unstructured":"Yu ML, Huang CF, Yeh ML, Tsai PC, Huang CI, Hsieh MH, et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients: a model for prioritization of treatment. Clin Cancer Res. 2017;23(7):1690\u20137.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/jgh.15538","volume":"36","author":"WF Hsu","year":"2021","unstructured":"Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol. 2021;36(10):2884\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1145_CR9","first-page":"259","volume":"11","author":"F Marcellin","year":"2017","unstructured":"Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017;11(3):259\u201368.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3350\/cmh.2024.0155","volume":"30","author":"CF Huang","year":"2024","unstructured":"Huang CF, Awad MH, Gal-Tanamy M, Yu ML. Unmet needs in the post-direct-acting antivirals era: the risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clin Mol Hepatol. 2024;30(3):326\u201344.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312.","journal-title":"J Hepatol"},{"issue":"7","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/jgh.13305","volume":"31","author":"WL Chuang","year":"2016","unstructured":"Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, et al. Ledipasvir\/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol. 2016;31(7):1323\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/liv.13082","volume":"36","author":"JH Kao","year":"2016","unstructured":"Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016;36(8):1101\u20137.","journal-title":"Liver Int"},{"issue":"5","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/jvh.12499","volume":"23","author":"SH Ahn","year":"2016","unstructured":"Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepatitis. 2016;23(5):358\u201365.","journal-title":"J Viral Hepatitis"},{"issue":"6","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12072-016-9726-5","volume":"10","author":"YS Lim","year":"2016","unstructured":"Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase IIIb study of ledipasvir\/sofosbuvir fixed-dose combination tablet in treatment-na\u00efve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hep Intl. 2016;10(6):947\u201355.","journal-title":"Hep Intl"},{"issue":"3","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/kjm2.12474","volume":"38","author":"TY Jang","year":"2022","unstructured":"Jang TY, Huang CF, Yeh ML, Huang CI, Dai CY, Tsai PC, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung J Med Sci. 2022;38(3):261\u20137.","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"1145_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Castera","year":"2005","unstructured":"Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350.","journal-title":"Gastroenterology"},{"issue":"4","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u201370.","journal-title":"Hepatol Int"},{"issue":"4","key":"1145_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100705","volume":"27","author":"N He","year":"2022","unstructured":"He N, Feng G, Hao S, Xu M, Liu J, Kong F, et al. The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis. Ann Hepatol. 2022;27(4): 100705.","journal-title":"Ann Hepatol"},{"key":"1145_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25\u201332.","journal-title":"J Hepatol"},{"issue":"6","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/ijms20061358","volume":"20","author":"T Kanda","year":"2019","unstructured":"Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;20(6):1358.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10(8):1917.","journal-title":"Cells"},{"issue":"3","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"5","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000445269","volume":"34","author":"Y Koyama","year":"2016","unstructured":"Koyama Y, Xu J, Liu X, Brenner DA. New developments on the treatment of liver fibrosis. Dig Dis. 2016;34(5):589\u201396.","journal-title":"Dig Dis"},{"issue":"3","key":"1145_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3350\/cmh.2022.0342","volume":"29","author":"CL Lin","year":"2023","unstructured":"Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29(3):605\u201322.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/hep4.1321","volume":"3","author":"T Jun","year":"2019","unstructured":"Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, et al. Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection. Hepatol Commun. 2019;3(4):493\u2013503.","journal-title":"Hepatol Commun"},{"issue":"6","key":"1145_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129053","volume":"10","author":"R Sasaki","year":"2015","unstructured":"Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Serum wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS ONE. 2015;10(6): e0129053.","journal-title":"PLoS ONE"},{"issue":"2","key":"1145_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","volume":"81","author":"T Reiberger","year":"2024","unstructured":"Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81(2):326\u201344.","journal-title":"J Hepatol"},{"issue":"4","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3350\/cmh.2024.0472","volume":"30","author":"CF Huang","year":"2024","unstructured":"Huang CF, Awad MH, Gal-Tanamy M, Yu ML. Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era. Clin Mol Hepatol. 2024;30(4):1023\u20135.","journal-title":"Clin Mol Hepatol"},{"key":"1145_CR30","doi-asserted-by":"crossref","unstructured":"Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, et al. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients\u2014a nationwide Taiwan HCV registry. J Formosan Med Assoc Taiwan yi zhi 2024:S0929-6646(24)00381-4.","DOI":"10.1016\/j.jfma.2024.08.013"},{"issue":"5","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.15102","volume":"49","author":"J Li","year":"2019","unstructured":"Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019;49(5):599\u2013608.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01145-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T08:24:12Z","timestamp":1747383852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01145-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming-Lung Yu: Research support from AbbVie, Abbott, BMS, Gilead, Merck and Roche. Consultant for AbbVie, Abbott, Ascletis, BMS, Gilead Sciences, J&J, Merck, Novartis, Pharmaessential and Roche. Speaker for AbbVie, Abbott, Ascletis, BMS, Gilead Sciences, Merck, Pharmaessential and Roche. Chung-Feng Huang: Speaker for AbbVie, BMS, Gilead Sciences, Merck, and Roche. Young-Suk Lim: Research support and consultant for Gilead Sciences. Young-Seok Kim: Speaker, consultant and grant support for Gilead Sciences. Jeong Huo, Rong-Nan Chien, Yang-Hyun Baek, Jia-Horng Kao, Ju-Hyun Kim, Ting-Tsang Chang, Kwan-Soo Byun, Jyh-Jou Chen, Sook-Hyang Jeong, Tsung-Hui Hu, Cheng-Yuan Peng, Won-Young Tak, Hrong-Yuan Wang, Seung-Kew Yoon, I-Shyan Sheen, Youn-Jae Lee, Yu-Chun Hsu, Pei-Chien Tsai, Ming-Lun Yeh, Sang-Hoon Ahn, Chai-Yen Dai, Seung-Woon Paik, Jee-Fu Huang, Yoon-Jun Kim, and Wan-Long Chuang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The study was approved by the institutional review board of Kaohsiung Medical University Hospital (KMUHIRB-F(I)-20160082), which conforms to the guidelines of the International Conference on Harmonization for Good Clinical Practice and was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}